The gene has been associated with obesity; this study aimed to determine the association between L- and S-alleles at the polymorphism with obesity in indigenous Mexican populations. A total of 362 individuals, 289 belonging to eight Native American (NA) groups; 40 Mexican mestizos; and 33 Caucasian Mennonites were enrolled in a cross-sectional study. High (≥90%) and low (<90%) NA ancestry was molecularly determined. A body mass index >30 kg/m was considered as obese. The L- and S-alleles of the locus were identified by PCR; the association between alleles and obesity was performed by logistic regression analysis. A significantly lower prevalence of obesity (35%) was observed in participants from communities with high NA ancestry ( < 0.005). Under a dominant heritance model the L-allele was associated with obesity in women with high NA ancestry (odds ratio [OR] 7.27; 95% confidence interval [CI] 1.6-32.5; = 0.009) but not in women with low NA ancestry (OR 0.83; 95% CI 0.3-2.2; = 0.71); no association was observed in men. Our results suggest that the L-allele is a risk factor for developing obesity in Mexican women with high NA ancestry (≥90%).
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1089/gtmb.2020.0068 | DOI Listing |
Eur J Pediatr
December 2024
Department of Clinical Pathology Faculty of Medicine, Mansoura University, Mansoura, Egypt.
Unlabelled: Children with Down syndrome (DS) have a higher incidence of overweight and obesity compared to typically developing peers. The fat mass and obesity-associated gene (FTO) is one of the early identified genes linked to obesity in various populations. To date, the FTO rs17817449 gene polymorphism has not been investigated in overweight/obese-DS (ODS) individuals.
View Article and Find Full Text PDFNutr Res
November 2024
Plants for Human Health Institute, North Carolina State University, Kannapolis, NC, USA; Department of Food, Bioprocessing, and Nutrition Sciences, North Carolina State University, Raleigh, NC, USA. Electronic address:
The flavan-3-ol (-)-epigallocatechin gallate (EGCG) blunts obesity in inbred mice, but human clinical trials have yielded mixed results. Genetic homogeneity in preclinical models may explain translational disconnect between rodents and humans. The Diversity Outbred (DO) mouse model provides genotype and phenotype variability for characterization of gene x environment (i.
View Article and Find Full Text PDFMedicine (Baltimore)
December 2024
Department of Cardiovascular Center, The First Affiliated Hospital, Key Laboratory of High Incidence Disease Research in Xinjiang, Ministry of Education, Xinjiang Medical University, Urumqi, China.
Recent studies have explored the impact of personality traits, including mood swings, on physical health. However, it remains unclear whether there is a direct cause-and-effect link between mood swings and cardiovascular diseases (CVDs). A STROBE-compliant cross-sectional observational study was conducted and analyzed using a two-sample Mendelian randomization (MR) approach to examine the potential causal relationship between mood swings and a range of CVDs, such as arrhythmia, artery aneurysm, coronary heart disease (CHD), heart failure, hypertension, stroke, ischemic stroke, and peripheral artery disease.
View Article and Find Full Text PDFJ Nutr Sci
December 2024
Cancer Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Diabetes Obes Metab
December 2024
TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Aims: To evaluate the predictive value of a contemporary type 2 diabetes (T2D) polygenic score (PGS) in detecting incident diabetes across a range of diabetes risk factors.
Materials And Methods: We analysed participants in the Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk (FOURIER) trial (ClinicalTrials.gov, number NCT0176463), which compared the efficacy of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor evolocumab versus placebo in lowering cardiovascular outcomes in participants with stable atherosclerotic cardiovascular disease and LDL cholesterol levels of 70 mg/dL (1.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!